These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38214322)

  • 1. PSMA PET/MR is a New Imaging Option for Identifying Glioma Recurrence and Predicting Prognosis.
    Xiong M; Chen Z; Zhou C; Yang X; Hu W; Jiang Y; Zheng R; Fan W; Mou Y; Lin X
    Recent Pat Anticancer Drug Discov; 2024; 19(3):383-395. PubMed ID: 38214322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. O-(2-[(18)F]fluoroethyl)-L-tyrosine uptake is an independent prognostic determinant in patients with glioma referred for radiation therapy.
    Sweeney R; Polat B; Samnick S; Reiners C; Flentje M; Verburg FA
    Ann Nucl Med; 2014 Feb; 28(2):154-62. PubMed ID: 24272067
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Akgun E; Akgun MY; Selçuk HH; Uzan M; Sayman HB
    Eur J Radiol; 2020 Sep; 130():109199. PubMed ID: 32763474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of 18F-FET PET/CT in newly diagnosed WHO 2016 high-grade glioma.
    Dissaux G; Basse V; Schick U; El Kabbaj O; Auberger B; Magro E; Kassoul A; Abgral R; Salaun PY; Bourhis D; Querellou S
    Medicine (Baltimore); 2020 Jan; 99(5):e19017. PubMed ID: 32000446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment and prospective validation of an SUV
    Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
    Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
    [No Abstract]   [Full Text] [Related]  

  • 7. Diagnostic value of integrated
    Zeng Y; Leng X; Liao H; Jiang G; Chen P
    Prostate Int; 2022 Jun; 10(2):108-116. PubMed ID: 35510079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ga-68 PSMA PET/CT in recurrent high-grade gliomas: evaluating PSMA expression in vivo.
    Kumar A; ArunRaj ST; Bhullar K; Haresh KP; Gupta S; Ballal S; Yadav M; Singh M; Damle NA; Garg A; Tripathi M; Bal C
    Neuroradiology; 2022 May; 64(5):969-979. PubMed ID: 34648046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glioma Recurrence Versus Radiation Necrosis: Single-Session Multiparametric Approach Using Simultaneous O-(2-18F-Fluoroethyl)-L-Tyrosine PET/MRI.
    Jena A; Taneja S; Gambhir A; Mishra AK; Dʼsouza MM; Verma SM; Hazari PP; Negi P; Jhadav GK; Sogani SK
    Clin Nucl Med; 2016 May; 41(5):e228-36. PubMed ID: 26859208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymph node standardized uptake values at pre-treatment
    Jeong Y; Baek S; Park JW; Joo JH; Kim JS; Lee SW
    Br J Radiol; 2017 Mar; 90(1071):20160239. PubMed ID: 28008776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 68Ga-Prostate-Specific Membrane Antigen-11 PET/CT: A New Imaging Option for Recurrent Glioblastoma Multiforme?
    Kunikowska J; Kuliński R; Muylle K; Koziara H; Królicki L
    Clin Nucl Med; 2020 Jan; 45(1):11-18. PubMed ID: 31663868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 68 Ga-PSMA-11 PET/CT Imaging in Brain Gliomas and Its Correlation With Clinicopathological Prognostic Parameters.
    Verma P; Singh BK; Sudhan MD; Singh RK; Bagul SD; Chandak AR; Soni BK; Shelly D; Basu S
    Clin Nucl Med; 2023 Dec; 48(12):e559-e563. PubMed ID: 37883060
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Zhou W; Wen J; Hua F; Xu W; Lu X; Yin B; Geng D; Guan Y
    Eur J Radiol; 2018 Jul; 104():26-32. PubMed ID: 29857862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET/CT using
    Liu D; Cheng G; Ma X; Wang S; Zhao X; Zhang W; Yang W; Wang J
    J Neuroimaging; 2021 Jul; 31(4):733-742. PubMed ID: 34021667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of
    Verger A; Filss CP; Lohmann P; Stoffels G; Sabel M; Wittsack HJ; Kops ER; Galldiks N; Fink GR; Shah NJ; Langen KJ
    Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2257-2265. PubMed ID: 28831534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Prospective Comparison of
    Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
    Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy.
    Sjöholm T; Korenyushkin A; Gammelgård G; Sarén T; Lövgren T; Loskog A; Essand M; Kullberg J; Enblad G; Ahlström H
    Cancer Imaging; 2022 Dec; 22(1):76. PubMed ID: 36575477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeatability of
    Lodge MA; Holdhoff M; Leal JP; Bag AK; Nabors LB; Mintz A; Lesser GJ; Mankoff DA; Desai AS; Mountz JM; Lieberman FS; Fisher JD; Desideri S; Ye X; Grossman SA; Schiff D; Wahl RL
    J Nucl Med; 2017 Mar; 58(3):393-398. PubMed ID: 27688473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential for differentiation of glioma recurrence from radionecrosis using integrated
    Sogani SK; Jena A; Taneja S; Gambhir A; Mishra AK; D'Souza MM; Verma SM; Hazari PP; Negi P; Jadhav GK
    Neurol India; 2017; 65(2):293-301. PubMed ID: 28290392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential of Radiolabeled PSMA PET/CT or PET/MRI Diagnostic Procedures in Gliomas/Glioblastomas.
    Bertagna F; Albano D; Cerudelli E; Gazzilli M; Giubbini R; Treglia G
    Curr Radiopharm; 2020; 13(2):94-98. PubMed ID: 31625482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.